Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Grows By 135.3%

OnKure Therapeutics, Inc. (NASDAQ:OKUR) was the target of a significant increase in short interest during the month of February. As of February 13th, there was short interest totaling 33,385 shares, an increase of 135.3% from the January 29th total of 14,187 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average trading volume of 101,537 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 101,537 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of research firms have issued reports on OKUR. Wall Street Zen upgraded shares of OnKure Therapeutics to a “sell” rating in a report on Saturday, November 1st. Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a research report on Monday, December 22nd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $32.00.

Hedge Funds Weigh In On OnKure Therapeutics

Large investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of OnKure Therapeutics in the 2nd quarter valued at about $25,000. Bailard Inc. purchased a new position in OnKure Therapeutics in the second quarter valued at approximately $34,000. Jane Street Group LLC acquired a new position in OnKure Therapeutics during the fourth quarter valued at approximately $56,000. Barclays PLC grew its stake in OnKure Therapeutics by 4,286.8% during the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after buying an additional 26,621 shares during the period. Finally, Rangeley Capital LLC acquired a new stake in shares of OnKure Therapeutics in the second quarter worth $71,000. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

OnKure Therapeutics Stock Down 1.8%

NASDAQ:OKUR opened at $2.66 on Friday. OnKure Therapeutics has a fifty-two week low of $1.70 and a fifty-two week high of $5.60. The firm’s 50 day moving average is $2.76 and its two-hundred day moving average is $2.82. The company has a market cap of $36.04 million, a P/E ratio of -0.56 and a beta of 0.46.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.